

Rachael A Mccloy

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1336881/publications.pdf>

Version: 2024-02-01

24
papers

1,474
citations

623734

14
h-index

752698

20
g-index

30
all docs

30
docs citations

30
times ranked

4007
citing authors

#	ARTICLE	IF	CITATIONS
1	Partial inhibition of Cdk1 in G ₂ phase overrides the SAC and decouples mitotic events. <i>Cell Cycle</i> , 2014, 13, 1400-1412.	2.6	773
2	Transient tissue priming via ROCK inhibition uncouples pancreatic cancer progression, sensitivity to chemotherapy, and metastasis. <i>Science Translational Medicine</i> , 2017, 9, .	12.4	208
3	Global Phosphoproteomic Mapping of Early Mitotic Exit in Human Cells Identifies Novel Substrate Dephosphorylation Motifs. <i>Molecular and Cellular Proteomics</i> , 2015, 14, 2194-2212.	3.8	63
4	Tamoxifen-Induced Epigenetic Silencing of Oestrogen-Regulated Genes in Anti-Hormone Resistant Breast Cancer. <i>PLoS ONE</i> , 2012, 7, e40466.	2.5	54
5	BCL-2 Hypermethylation Is a Potential Biomarker of Sensitivity to Antimitotic Chemotherapy in Endocrine-Resistant Breast Cancer. <i>Molecular Cancer Therapeutics</i> , 2013, 12, 1874-1885.	4.1	45
6	MASTL overexpression promotes chromosome instability and metastasis in breast cancer. <i>Oncogene</i> , 2018, 37, 4518-4533.	5.9	45
7	PP1 initiates the dephosphorylation of MASTL, triggering mitotic exit and bistability in human cells. <i>Journal of Cell Science</i> , 2016, 129, 1340-54.	2.0	44
8	Global characterization of signalling networks associated with tamoxifen resistance in breast cancer. <i>FEBS Journal</i> , 2013, 280, 5237-5257.	4.7	36
9	Inhibition of activin signaling in lung adenocarcinoma increases the therapeutic index of platinum chemotherapy. <i>Science Translational Medicine</i> , 2018, 10, .	12.4	32
10	The E3 ubiquitin ligase UBR5 regulates centriolar satellite stability and primary cilia. <i>Molecular Biology of the Cell</i> , 2018, 29, 1542-1554.	2.1	27
11	Mechanisms regulating phosphatase specificity and the removal of individual phosphorylation sites during mitotic exit. <i>BioEssays</i> , 2016, 38, S24-32.	2.5	26
12	Deep multi-region whole-genome sequencing reveals heterogeneity and gene-by-environment interactions in treatment-naive, metastatic lung cancer. <i>Oncogene</i> , 2019, 38, 1661-1675.	5.9	26
13	Identification of PUMA as an estrogen target gene that mediates the apoptotic response to tamoxifen in human breast cancer cells and predicts patient outcome and tamoxifen responsiveness in breast cancer. <i>Oncogene</i> , 2011, 30, 3186-3197.	5.9	21
14	The tumor suppressor Hic1 maintains chromosomal stability independent of Tp53. <i>Oncogene</i> , 2018, 37, 1939-1948.	5.9	18
15	Role of endoplasmic reticulum stress induction by the plant toxin, persin, in overcoming resistance to the apoptotic effects of tamoxifen in human breast cancer cells. <i>British Journal of Cancer</i> , 2013, 109, 3034-3041.	6.4	14
16	A non-genetic, cell cycle-dependent mechanism of platinum resistance in lung adenocarcinoma. <i>ELife</i> , 2021, 10, .	6.0	14
17	Retinal ganglion cell-specific genetic regulation in primary open-angle glaucoma. <i>Cell Genomics</i> , 2022, 2, 100142.	6.5	9
18	Dataset from the global phosphoproteomic mapping of early mitotic exit in human cells. <i>Data in Brief</i> , 2015, 5, 45-52.	1.0	8

#	ARTICLE	IF	CITATIONS
19	Analysis of pulsed cisplatin signalling dynamics identifies effectors of resistance in lung adenocarcinoma. <i>ELife</i> , 2020, 9, .	6.0	7
20	SILAC kinase screen identifies potential MASTL substrates. <i>Scientific Reports</i> , 2022, 12, .	3.3	3
21	Activin-A, Growth Differentiation Factor-11 and Transforming Growth Factor- β 2 as predictive biomarkers for platinum chemotherapy in advanced non-small cell lung cancer. <i>Cancer Treatment and Research Communications</i> , 2022, 32, 100576.	1.7	1
22	Mechanisms regulating phosphatase specificity and the removal of individual phosphorylation sites during mitotic exit. <i>Inside the Cell</i> , 2016, 1, 27-35.	0.4	0
23	Using single cell genomics to change the treatment of lung cancer.. <i>Journal of Clinical Oncology</i> , 2019, 37, e20563-e20563.	1.6	0
24	Activin as a biomarker for platinum resistance in non-small cell lung cancer.. <i>Journal of Clinical Oncology</i> , 2020, 38, e21737-e21737.	1.6	0